Neutrophils play a central role in host defenses against infectious microbial pathogens.
Introduction
Myeloid cells, including neutrophils and macrophages, play an essential role for host defenses against infectious microbial pathogens (Nathan, 2006) . In response to inflammatory stimuli, neutrophils are activated through a vast array of cell surface receptors, such as Fc receptors for IgG, β2 integrins, complement receptors, chemokines, cytokine receptors and Toll-like receptors, and mediate phagocytosis, degranulation of anti-microbial substances or secretion of inflammatory mediators. However, the molecular interactions that trigger anti-microbial functions of neutrophils are incompletely understood.
We have recently identified paired activating and inhibitory receptors, myeloid-associated immunoglobulin (Ig)-like receptor (MAIR)-I and MAIR-II (Yotsumoto et al., 2003) , which are also named as CLM8/LMIR1 and CLM4/LMIR2/DIgR1, respectively (Luo et al., 2001 ) (Kumagai et al., 2003) (Chung et al., 2003) . MAIR-I is preferentially expressed on myeloid cells, including macrophages, neutrophils, dendritic cells (DC) and bone marrow-derived cultured mast cells (Yotsumoto et al., 2003) and mediates an inhibitory signal through immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic portion.
On the other hand, MAIR-II, expressed on macrophages, associates with either immunoreceptor tyrosine-based activating motif (ITAM)-containing adaptors DAP12 or FcRγ chain and mediates an activating signal, resulting in inflammatory cytokine secretion from macrophages (Yotsumoto et al., 2003) (Nakahashi et al., 2007) . By screening a database for the mouse genome, we and others found that MAIR-I and MAIR-II are members of a multigene family consisting of nine genes on a small segment of mouse chromosome 11 (our unpublished observation and (Chung et al., 2003) ).
In this study, we generated monoclonal antibodies (mAbs) against a member of the family, MAIR-IV, and investigated its cellular distribution and functional role in immune responses. We show that MAIR-IV is a novel triggering receptor on neutrophils and is involved in inflammatory responses.
Materials and methods

Antibodies
Anti-MAIR-IV mAbs TX-69 and TX81 (rat IgG2a and IgG2b, respectively) were generated and F(ab') 2 fragments of TX-69 mAb were prepared in our laboratory, as described (Yotsumoto et al., 2003) . Alexa Fluor 647-conjugated F(ab') 2 fragments of TX69 was prepared by using Alexa Fluor 647 monoclonal antibody labeling kit (Molecular Probes, Eugene, Oregon). Control rat and mouse IgG, anti-CD11b (Mac-1), anti-Ly6G (Gr-1), anti-B220, anti-CD3, anti-CD11c, DX-5, and anti-CD32/16 (2.4G2) mAbs were purchased from BD Biosciences (San Jose, CA). Anti-Flag mAb, anti-FcεRIγ (FcRγ chain) mAb and horse-radish peroxidase (HRP)-conjugated streptavidin (SA) were purchased from Sigma-Aldrich (St Louis, MO), Upstate Biotechnology (Lake Placid, NY) and Amersham Biosciences (Piscataway, NJ), respectively. To exclude endotoxin contamination, all antibodies were treated with Polymyxin B (BIO-RAD, CA), resulting in endotoxin contamination at less than 100 pg/mg of mAb, as determined by Limulus Color KY Test (Wako, Osaka, Japan).
Mice, Cells and transfectants
FcRγ
-/-mice were provided by T. Takai (Tohoku University, Sendai, Japan). C57BL/6J mice were purchased from Clea Japan (Tokyo, Japan). Neutrophils from the bone marrow were purified by using a MACS selection system using biotin-labeled anti-Gr-1, followed by streptavidin-MicroBeads (Miltenyi Biotec, Bergisch Granbach, Germany) and those from peritoneal cavity were collected 6 hrs after the 2.4% thioglycollate i.p.
injection. Macrophages, dendritic cells (DC) and mast cells were generated by culture of BM cells in the presence of M-CSF (50 ng/ml) for 5 days, GM-CSF (10 ng/ml) for 9 days and IL-3 (4 ng/ml) plus SCF (10 ng/ml) for 5 weeks, respectively. Purity of each lineage of cells was more than 95%, as determined by flow cytometry. All experiments were performed according to the guidelines of the animal ethics committee of the University of Tsukuba. BW5147, RAW264.7 and RBL-2H3 transfectants stably expressing MAIR-IV, MAIR-II or MAIR-V were established, as described (Yotsumoto et al., 2003) .
Immunoprecipitation and western blotting
To analyze association of MAIR-IV with FcRγ chain, RAW264 or RBL-2H3 transfectants, or peritoneal exudative macrophages were lysed with a lysis buffer containing 1% digitonin (Calbiochem, San Diego, CA), 0.12% Triton-X (Sigma-Aldrich), 150 mM NaCl, 20 mM triethanolamine and protease inhibitors.
Lysates were subjected to immunoprecipitation with anti-Flag M2 affinity gel (Sigma Buffer (Piece Chemical Co.) was used according to the manufacture's instruction.
Cytokine production
Peritoneal exudative cells (PECs) and neutrophils were stimulated with plate-coated F(ab') 2 fragments of anti-MAIR-IV mAb (TX69) or control IgG and culture supernatants were subjected to ELISA assay for TNF-α and IL-6 (BD Biosciences, San
Jose, CA).
Results and discussion
Identification of MAIR-IV
We cloned all the full-length cDNAs of the MAIR family genes other than MAIR-I and MAIR-II by PCR from the spleen of C57BL/6 mice and designated them as MAIR-III to MAIR-IX, based on a phylogenetic tree analysis (Fig1A, B) . The MAIR family was found to be a murine counterpart of the human CMRF-35 (CD300) family (Cantoni et al., 1999 ) (Clark et al., 2000 ) (Clark et al., 2002) , which is located on human chromosome 17, syntenic region of mouse chromosome 11 (Fig 1A) . We found that one of the genes, MAIR-IV, has a short cytoplasmic tail (24 aa) with no signaling motif and a negatively charged glutamic acid (E) in its transmembrane (TM) region. The
Ig-like domain of MAIR-IV in the extracellular portion has 91% identity with that of MAIR-V at the amino acid level. In contrast to MAIR-IV, MAIR-V has a long cytoplasmic tail containing two consensus immunoreceptor tyrosine-based inhibitory motif (ITIM), suggesting that MAIR-IV and MAIR-V constitute paired activating and inhibitory receptors.
MAIR-IV is preferentially expressed on neutrophils and macrophages
MAIR-IV and MAIR-V were also named as CLM5 and CLM1/DIgR2 (Chung et al., 2003 ) (Fujimoto et al., 2006 ) (Shi et al., 2006) , respectively. Although expression of MAIR-IV/CLM5 mRNA was reported to be detected in myeloid cells (Fujimoto et al., 2006) , its protein expression profile has been undetermined because of lack of monoclonal antibodies. Therefore, functional characteristics of MAIR-IV in immune responses has remained unclear. Here, we generated monoclonal antibodies (TX69 and TX81 mAbs) against MAIR-IV by immunizing a rat with a mouse T cell leukemia cell line BW5147 transfected with Flag-tagged MAIR-IV. To confirm the specificity of these mAbs to MAIR-IV, we also established BW5147 transfectant stably expressing
MAIR-I, MAIR-II, MAIR-V tagged with Flag at the N-terminus. TX69 and TX81
mAbs specifically stained the transfectant expressing MAIR-IV, but not those expressing MAIR-I, MAIR-II or MAIR-V, indicating that these mAbs are specific to MAIR-IV (Fig 2A and data not shown) . Analyses by flow cytometry by using Alexa-657-conjugated F(ab') 2 fragments of TX69 mAb showed that MAIR-IV was preferentially expressed on Gr-1 high /Mac-1 + neutrophils from the peripheral blood, bone marrow, peritoneal cavity and spleen (Fig.2B) . MAIR-IV was also expressed on Mac-1 + /Gr-1 -macrophages from the spleen and bone marrow and CD11c + dendritic cells (DC), but not on T, B, NK cells or bone marrow-derived cultured mast cells (Fig.2B) . Whereas MAIR-II was coimmunoprecipitated with DAP12, as previously reported by our group (Yotsumoto et al., 2003) (Nakahashi et al., 2007) , MAIR-IV was not (Fig 3B) .
FcRγ chain physically associates with MAIR-IV and is involved in cell surface expression of MAIR-IV in primary cells
MAIR-IV contains
These results indicated the physical association of transfected MAIR-IV with the FcRγ chain, but not with DAP12, in these transfectants. Furthermore, we also found that endogeneous MAIR-IV was also coimmunoprecipitated with FcRγ chain in lysates of peritoneal macrophages stimulated with thioglycollate from wild type (WT), but not
, mice. In addition, cell surface expression of MAIR-IV was significantly down-regulated on bone marrow and peritoneal neutrophils from FcRγ -/-mice, compared with those from WT mice (Fig. 3D) . Moreover, although intraperitoneal treatment with thioglycollate significantly up-regulated cell surface expression of MAIR-IV on macrophages, this enhancement was not detected on those from FcRγ -/-mice ( Fig. 3D) . Because mRNA expression of MAIR-IV in FcRγ -/-peritoneal macrophages was comparable to that in WT peritoneal macrophages (data not shown), cell-surface expression of MAIR-IV largely depended on FcRγ chain expression.
Taken together, these results indicated that FcRγ chain physically associates with MAIR-IV and is involved in cell surface expression of MAIR-IV in primary neutrophils and macrophages.
MAIR-IV is a triggering receptor on neutrophils
Because MAIR-IV associates with FcRγ chain, it may mediates an activating signal in neutrophils. To address this issue, neutrophils were purified from the BM and peritoneal cavity and stimulated with plate-coated F(ab') 2 fragments of anti-MAIR-IV mAb. As shown in Fig. 4A , TNF-α secretion from neutrophils was significantly increased after the stimulation with anti-MAIR-IV. Similarly, stimulation of PEC with plate-coated F(ab') 2 fragments of anti-MAIR-IV mAb significantly augmented secretion of IL-6 as well as TNF-α (Fig. 4B) . These results indicated that MAIR-IV is a novel activating receptor on neutrophils. Thus, MAIR-IV may regulate neutophils activation and involved in innate immunity. To clarify the in vivo role of MAIR-IV in immune responses, identification of the ligand for MAIR-IV should be required.
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